EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Christopher D Lao iD, James Moon, Vincent T Ma iD, John P Fruehauf, Lawrence E Flaherty, Martin J Bury, William G Martin, Howard Gross, Wallace Akerley, Judith O Hopkins, Sapna P Patel, Vernon K Sondak iD und 1 weitere

Cancer · 2025

DOI: 10.1002/cncr.35587 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Christopher D Lao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Rogel Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Melanoma, Pyridinium Compounds, Indolizines, Cyclic N-Oxides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Institute of the National Institutes of Health, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cell cycle inhibition is an established therapeutic approach for some cancers. A multicenter, single‐arm, phase 2 trial ( ClinicalTrials.gov identifier NCT00937937) of the cyclin‐dependent kinase inhibitor SCH 727965 (NSC 747135; dinaciclib) was conducted in patients with metastatic melanoma to determine its clinical activity.

Methods

Patients with metastatic melanoma of cutaneous or mucosal origin were eligible if they had zero to one previous treatments, a Zubrod performance status of 0–1, and adequate organ function. SCH 727965 50 mg/m 2 was given intravenously every 3 weeks until progression. Co‐primary end points were 1‐year overall survival (OS) and 6‐month progression‐free survival (PFS).

Results

Seventy‐two patients were enrolled from July 1, 2009, to November 1, 2010, at 24 institutions. Sixty‐eight percent of patients had M1c disease, and 43% had elevated lactate dehydrogenase levels. Twenty‐eight patients (39%) experienced grade 4 adverse events, including 20 cases of neutropenia. Sixty‐seven patients were evaluable for response. There was a response in zero of 67 patients (95% confidence interval [CI], 0%–5%), and stable disease was observed in 21%. The estimated median PFS was 1.4 months (95% CI, 1.4–1.5 months), and the 6‐month PFS rate was 6% (2%–13%). The median OS was 8.2 months (95% CI, 5.5–10.5 months), and the 1‐year OS rate was 38% (95% CI, 26%–49%).

Conclusions

This multicenter, US National Cancer Institute Cancer Therapy Evaluation Program‐sponsored trial of SCH 727965 was conducted at a time when the current generation of effective therapies for melanoma were not available. Although the null hypothesis of 1‐year OS was rejected, the minimal PFS impact and substantive toxicity indicated that this regimen lacks justification for further investigation as a single agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaPyridinium CompoundsIndolizinesCyclic N-OxidesNeoplasm StagingHumansMaleMiddle AgedFemaleAgedAdultAged, 80 and overBridged Bicyclo Compounds, HeterocyclicSkin NeoplasmsProgression-Free Survival

Stichwörter der Autor:innen

CDK inhibitioncyclin‐dependent kinase (CDK)dinaciclibmelanoma

Substanzen

dinaciclibPyridinium CompoundsIndolizinesCyclic N-OxidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Rogel Cancer Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
  • Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Southwest Oncology Group Statistical Center, Seattle, Washington, USA.
  • Carbone Cancer Center, Department of Oncology, University of Wisconsin, Madison, Wisconsin, USA.
  • University of California at Irvine, Orange, California, USA.
  • Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.

ORCID-Profile: Christopher D Lao, Vincent T Ma, Vernon K Sondak

Förderung

  • National Cancer Institute of the National Institutes of Health
  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Lao, C. D., Moon, J., Ma, V. T., Fruehauf, J. P., Flaherty, L. E., Bury, M. J., Martin, W. G., Gross, H., Akerley, W., Hopkins, J. O., Patel, S. P., Sondak, V. K., & Ribas, A. (2025). Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. https://doi.org/10.1002/cncr.35587

Vancouver

Lao CD, Moon J, Ma VT, Fruehauf JP, Flaherty LE, Bury MJ, et al. Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Cancer. 2025. doi:10.1002/cncr.35587

BibTeX
@article{Lao2025,
  author = {Lao, Christopher D and Moon, James and Ma, Vincent T and Fruehauf, John P and Flaherty, Lawrence E and Bury, Martin J and Martin, William G and Gross, Howard and Akerley, Wallace and Hopkins, Judith O and Patel, Sapna P and Sondak, Vernon K and Ribas, Antoni},
  title = {Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35587}
}
Kostenlos starten →